Management Team

ScreenCancer AS (Europe)

Christian Horn, CEO

Christian Horn founded ScreenCancer in 2007. Previous to ScreenCancer, he was CEO of NorDiag ASA, a molecular diagnostics company developing and commercializing tests for early colorectal cancer detection where he led the company’s successful IPO in 2006. Christian was previously CEO, Novel Diagnostics ASA and was Executive Chairman of PlasmAcute AS, for which he still serves as Director.

Prof. Dr. Med Dagfinn Øgreid, Director of Oncology

Prof. Dagfinn Øgreid is Medical Director of NorDiag ASAand a co-founder of ScreenCancer. Dr. Øgreid consults actively in oncology and was formerly Director of the Dept. of Hematology and Oncology at University Hospital, Stavanger. Dr. Øgreid holds an MD/PhD from the University of Bergen and has over 25 years of international research experience.

Marit Austgulen Wick, Chief Financial Officer

Before joining ScreenCancer, Ms. Wick was CFO of NorDiag ASA. Prior to this Marit was Group Accounting Director for the listed industrial conglomerate company Rieber & Søn ASA. While with Rieber & Søn ASA, she was also involved in strategy, organization and M&A aspects of the business. Ms. Wick is a chartered accountant (HRS).

Mette Valeur, VP Operations & Customer Service

Before joining ScreenCancer, Mette was CEO at VIA Travel Norway. She has a broad experience as manager of operations and customer services from different companies. Her knowledge of customer relations, IT-systems and processes in Vesta- /Skandia Insurance, Elkjøp Nordic/Dixons and VIA Travel is of great value for ScreenCancer. Mette holds an MBA from Oslo Business School, and management courses at Henley Management School and Harvard Business School.

ScreenCancer USA

David Nikka, CEO

David Nikka has more than 20 years of experience in the healthcare, biotechnology and medical device industries. Prior to co-founding ScreenCancer, Mr. Nikka held the positions of Chief Operating Officer and Senior Vice President of Corporate Development for EXACT Sciences Corporation, a publically-traded company developing and commercializing DNA-based colorectal cancer screening tests. Previous to EXACT, Mr. Nikka was Vice President, Strategic Development for ABIOMED, Inc., a cardiovascular medical products company and leader in the field of heart-assist and replacement devices. Earlier in his career, Mr. Nikka held several management positions at Genzyme Corporation including Vice President, Site Manager for Genetic Design, a paternity and identity testing laboratory and Vice President, Human Resources of Genzyme Genetics.

Margaret Johnston, Senior Vice President of Sales

Ms. Johnston has over 35 years of sales and marketing experience in the clinical laboratory industry. She held several key management roles with both SmithKline Beecham and Quest Diagnostics and has been involved in all phases of the clinical laboratory business including the physician, hospital, genetics, employer and managed care markets. Prior to joining ScreenCancer, Margaret was Director of Strategic Accounts for EXACT Sciences Corporation where she was involved in all sales activities for the PreGen-Plus™ Non-Invasive DNA test for colorectal cancer. This included the management of sales pilots for the product launch, coordination of sales efforts with EXACT’s national laboratory partner, and significant outreach and support of non-profit colorectal cancer screening programs.